Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • Services & Support
  • Cart
  • Transplant Indications and Outcomes
    • HLA Today
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • Myelodysplastic Syndromes (MDS)
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
      • Myeloproliferative Neoplasms
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • Order Kits
    • HLA Typing for Family Members
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Medical Education & Research
    • Browse News
      • Results of Study on COVID-19 Vaccine Response in Hematopoietic Cell Transplant Patients Published in eClinicalMedicine
    • Browse Research
    • Education Catalog
      • HLA and Search Strategy Resources
      • GVHD Interactive Provider Network Virtual Learning Series
    • Materials Catalog
    • HCT Presentation Slides
    • About Our Research
    • Transplant Enews
  • Resources
    • Patient Resources
    • Financial Resources
    • Obstetrician Resources
    • Technique Videos
    • Umbilical Cord Blood Collection Training for Public Donation
    • Local Provider Partnership Program
  • HLA Today
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • Order Kits
  • HLA Typing for Family Members

Disease-Specific Indications and Outcomes

  • AML - Adult
  • AML - Pediatric
  • ALL - Adult
  • ALL - Pediatric
  • Myelodysplastic Syndromes (MDS)
  • CML
  • CLL
  • NHL
  • Hodgkin Lymphoma
  • Multiple Myeloma
  • Severe Aplastic Anemia & Marrow Failure
  • Sickle Cell Disease
  • Immune Deficiency Diseases
  • Inherited Metabolic Disorders
  • Thalassemia
  • Other Diseases
  • Myeloproliferative Neoplasms
Research Spotlight
  • Novel cytogenetic-based risk scores predict HCT outcomes for patients with CLL

    September 2019

  • New Prognostic System for Patients with Relapsed Follicular Lymphoma

    May 2018

  • Experts Debate Allo-HCT for Patients with Hodgkin Lymphoma Relapsing After Auto-HCT

    May 2018

  • Transplant Indications and Outcomes
  • Disease-Specific Indications and Outcomes
  • NHL
  • Email
  • Print This Page

Related Resources

  • Subscribe to the Latest NHL Research
  • HCT Guidelines App

Patient Resources

  • Transplant and NHL (PDF)
  • Transplant Outcomes and Treatment Decisions
  • Transplant Basics Booklet
  • Transplant Basics Videos

Non-Hodgkin Lymphoma (NHL)

Non-Hodgkin lymphomas (NHL) are a highly heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes or natural killer (NK) cells. In the United States, B-cell NHL represents 80-85% of cases; T-cell NHL, 15-20%; and NK NHL is rare. Most hematopoietic cell transplantation (HCT) performed for NHL is autologous, but in some cases, physicians may perform allogeneic HCT for particularly high-risk relapsed or refractory disease. [1, 2] 

Figure 1 shows the increase by age group in the number of unrelated donor transplants facilitated by the National Marrow Donor Program® (NMDP)/Be The Match®, including patients with NHL.

Figure 1.  Trend of Allogeneic HCT for Malignant Diseases in Adult and Pediatric Recipients 

Figure 1.  Trend of Allogeneic HCT for Malignant Diseases in Adult and Pediatric Recipients

Download slide

Outcomes  

Data in this section have been prepared by the CIBMTR® (Center for International Blood and Marrow Transplant Research®). The CIBMTR is a research collaboration between the NMDP/Be The Match and the Medical College of Wisconsin. 

Figure 2. Allogeneic HCT Volume Over Time  

Figure 2. Allogeneic HCT Volume Over Time

Download slide  

Figure 3. U.S. Volume of Autologous HCT Over Time 

Figure 3. U.S. Volume of Autologous HCT Over Time

Download slide  

Figure 4. U.S. Volume of Autologous Diffuse Large B-Cell Lymphoma (DLBCL) HCT  

Figure 4. U.S. Volume of Autologous Diffuse Large B-Cell Lymphoma (DLBCL) HCT

Download slide  

Figure 5. Survival, Autologous or Allogeneic Follicular Lymphoma (FL) HCT  

 Figure 5. Survival, Autologous or Allogeneic Follicular Lymphoma (FL) HCT

Download slide  

Figure 6. Survival Trends, Autologous FL HCT Over Time  

 Figure 6. Survival Trends, Autologous FL HCT Over Time

Download slide  

Figure 7. Survival Trends, Autologous DLBCL HCT Over Time  

 Figure 7. Survival Trends, Autologous DLBCL HCT Over Time

Download slide  

Figure 8. Survival, Autologous or Allogeneic Mantle Cell Lymphoma (MCL) HCT 

 Figure 8. Survival, Autologous or Allogeneic Mantle Cell Lymphoma (MCL) HCT

Download slide  

Figure 9. Survival Trends, Autologous MCL HCT  

 Figure 9. Survival Trends, Autologous MCL HCT

Download slide  

HCT Consultation Timing Guidelines  

The National Marrow Donor Program® (NMDP)/Be The Match® and the American Society for Transplantation and Cellular Therapy (ASTCT) have jointly developed guidelines for transplant consultation and referral timing based on disease characteristics. [1] The National Comprehensive Cancer Network Clinical Practice Guidelines (NCCN Guidelines®) were consulted in developing these guidelines and are a valuable tool in determining risk stratification. [3] 

Our guidelines highlight disease categories that include patients at risk for disease progression and who should be referred for a consultation for autologous or allogeneic transplantation. [1]

Transplant Consultation Guidelines: NHL  

Follicular Lymphoma 

  • Poor response to initial treatment 
  • Initial remission duration <24 months 
  • First relapse 
  • Transformation to diffuse large B-cell lymphoma 

Diffuse Large B-Cell Lymphoma 

  • Primary induction failure, including residual PET avid disease 
  • First relapse 
  • CR2 or subsequent remission 
  • Double or triple hit (MYC and BCL-2 and/or BCL-6) – at diagnosis
  • Primary CNS lymphoma at diagnosis PIF or first relapse 

High Grade B-Cell Lymphoma 

  • MYC and BCL-2 and/or BCL-6 rearrangements 
  • Primary induction failure 
  • CR1 
  • First relapse 
  • CR2 or subsequent remission 

Mantle T-Cell Lymphoma 

  • At diagnosis 
  • First relapse 
  • Bruton's tyrosine kinase (BTK) intolerant or resistant disease  

Mature T-Cell Lymphoma 

  • CR1 
  • First relapse 

Other High-Risk Lymphomas 

  • At diagnosis  

Download as a slide

View complete HCT Consultation Timing Guidelines

CAR-T Cell Therapy Video for Patients 

Chimeric antigen receptor T-cell (CAR-T) therapy is a new treatment focus for hematologic malignancies. Though some limitations are a barrier, new research shows promising safety and efficacy with targeted gene therapy for the treatment of NHL. [4] 

In this easy-to-understand video, Linda J. Burns, MD, former Vice President, Health Services Research, and Scott Kerwin, RN, MN, CCRC, CCRN, former Clinical Trial Patient Education Specialist at the NMDP/Be The Match, explain what CAR-T therapy is, who it may help, what the treatment is like, potential risks and benefits, questions to ask your doctor, and more. View the video and share it with patients and caregivers who are looking for information on CAR-T therapy as a treatment option. 

Clinical Trials Search and Support 

The NMDP/Be The Match offers the Be The Match® Jason Carter Clinical Trials Search and Support (CTSS) program, which can provide clinical trial navigation to your patients. The CTSS Program was created to help people with blood cancers or blood disorders and their families find and join clinical trials.

For more information, visit Clinical Trials Search and Support.  

References 

  1. National Comprehensive Cancer Network. B Cell Lymphomas. (Version 5.2022). Access
  2. Dreyling M, Ferrero S, Hermine O. How to manage mantle cell lymphoma. Leukemia. 2014; 28(11): 2117-2130. Access
  3. NMDP/Be The Match and ASTCT Recommended Timing for Transplant Consultation. Download (PDF)
  4. Zhang J., Hu Y., Yang J. et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature. 2022; 609: 369–374. Access  

  • Email
  • Print This Page

Slides may be downloaded and used without permission for one-time presentation or personal use.  For publication, use in print or web, or repeated presentations, please submit a Copyright Request Form.

Keep In Touch

  • Contact Us
  • Transplant Enews

Our Websites

  • Be The Match
  • Be The Match Mexico
  • Be The Match BioTherapies
  • CIBMTR
  • Jason Carter Clinical Trials Search
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2023 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright